Skip to Main Content

Author Details

Akbar Ali
University of Massachusetts Chan Medical School
2003
48
27
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36920025Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.Elife2023
37244161HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues.Eur J Med Chem2023
36446201Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease.Bioorg Chem2023
35183560Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance.J Mol Biol2022
35767698Phenylsulfamoyl Benzoic Acid Inhibitor of ERAP2 with a Novel Mode of Inhibition.ACS Chem Biol2022
33410674Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.Chem Rev2021
33619959Inhibiting HTLV-1 Protease: A Viable Antiviral Target.ACS Chem Biol2021
33503819Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.Viruses2021
34405680Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.J Med Chem2021
32234812Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.mBio2020
31868341Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.ACS Chem Biol2020
32672965Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.J Med Chem2020
30543749Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.ACS Infect Dis2019
31386368HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.J Med Chem2019
30990653Correction to Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.ACS Infect Dis2019
30034602Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants.ACS Med Chem Lett2018
30146168Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.Structure2018
28594175Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.J Med Chem2017
28298600Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.J Virol2017
26728557P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates.Genes Dev2016
27512818Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.J Am Chem Soc2016
26682473Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172.ACS Chem Biol2016
25961497Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.ACS Chem Biol2015
25243902Structural analysis of asunaprevir resistance in HCV NS3/4A protease.ACS Chem Biol2014
23594083Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance.ACS Chem Biol2013
24250277Efficient Computation of Small-Molecule Configurational Binding Entropy and Free Energy Changes by Ensemble Enumeration.J Chem Theory Comput2013
23904484Chemical screening identifies filastatin, a small molecule inhibitor of Candida albicans adhesion, morphogenesis, and pathogenesis.Proc Natl Acad Sci U S A2013
24012370Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.Chem Biol2013
23952265Testing the substrate-envelope hypothesis with designed pairs of compounds.ACS Chem Biol2013
22181350First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G.ACS Chem Biol2012
22708897Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.J Med Chem2012
22910833The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.PLoS Pathog2012
22555953Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication.ChemMedChem2012
20237088Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.J Virol2010
21994628Molecular Basis for Drug Resistance in HIV-1 Protease.Viruses2010
21084633Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.Proc Natl Acad Sci U S A2010
20958050Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.J Med Chem2010
20551309P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes.J Biol Chem2010
19193159Additivity in the analysis and design of HIV protease inhibitors.J Med Chem2009
19603446Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication.Chembiochem2009
18412349HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.J Am Chem Soc2008
18806783Small-molecule inhibition of HIV-1 Vif.Nat Biotechnol2008
17696512Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.J Med Chem2007
17539822Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.Chem Biol Drug Des2007
17149864Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.J Med Chem2006
15975509Dissecting RNA-interference pathway with small molecules.Chem Biol2005
15324818Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells.Chem Biol2004
12857725Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication.J Biol Chem2003
  • 1 - 48 of 48

Recommended Authors

Jiankun Lyu
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2015
Number of shared co-authors 2
Taha Y Taha
Gladstone Institutes
Career Start Year 2015
Number of shared co-authors 1
Peter K Quashie
College of Basic and Applied Sciences, University of Ghana
Career Start Year 2011
Number of shared co-authors 1
Ujjwal Rathore
University of California san francisco
Career Start Year 2010
Number of shared co-authors 2
Kris M White
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Career Start Year 2010
Number of shared co-authors 3
Sakshi Tomar
J. David Gladstone Institutes
Career Start Year 2009
Number of shared co-authors 1
Jonathan E Gable
Novartis Institute for Tropical Diseases
Career Start Year 2008
Number of shared co-authors 0
Xiaofei Jia
University of Massachusetts Dartmouth
Career Start Year 2008
Number of shared co-authors 1
Max W Chang
University of California San Diego
Career Start Year 2007
Number of shared co-authors 2
Nir London
The Weizmann Institute of Science
Career Start Year 2007
Number of shared co-authors 1
Jacob D Durrant
University of Pittsburgh
Career Start Year 2006
Number of shared co-authors 0
Xuexiang Zhang
Baruch S. Blumberg Institute
Career Start Year 2005
Number of shared co-authors 0
Priyadarshini Jaishankar
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 2005
Number of shared co-authors 2
Craig J Thomas
Center for Cancer Research, National Cancer Institute
Career Start Year 2001
Number of shared co-authors 1
Heather A Carlson
University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 1
Eric Feyfant
Schrodinger Inc.
Career Start Year 1997
Number of shared co-authors 0
Soumya S Ray
Lysosomal Therapeutics Inc.
Career Start Year 1997
Number of shared co-authors 0
Adam R Renslo
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1997
Number of shared co-authors 3
Andrew L Hopkins
University of Dundee
Career Start Year 1995
Number of shared co-authors 1
Hualiang Jiang
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Career Start Year 1994
Number of shared co-authors 0
Kelli Kuhen
Genomics Institute of the Novartis Research Foundation
Career Start Year 1992
Number of shared co-authors 0
Mark Namchuk
Blavatnik Institute, Harvard Medical School
Career Start Year 1990
Number of shared co-authors 0
Brian K Shoichet
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1989
Number of shared co-authors 3
Herman W T van Vlijmen
Leiden Academic Centre for Drug Research (LACDR), Leiden University
Career Start Year 1988
Number of shared co-authors 0
Diane Joseph-McCarthy
Boston University
Career Start Year 1987
Number of shared co-authors 0
William G Rice
University of Southampton Highfield Southampton SO17 1BJ UK.
Career Start Year 1986
Number of shared co-authors 0
Christophe L M J Verlinde
University of Washington
Career Start Year 1984
Number of shared co-authors 0
Daria J Hazuda
Merck & Co. Inc.
Career Start Year 1983
Number of shared co-authors 5
Ruben Abagyan
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Career Start Year 1981
Number of shared co-authors 0
Christine Humblet
Lilly Research Laboratories
Career Start Year 1977
Number of shared co-authors 1

Collaborators

Celia A Schiffer
University of Massachusetts Chan Medical School
Co-authored papers 38
Tariq M Rana
Institute for Genomic Medicine, University of California San Diego
Co-authored papers 19
Michael K Gilson
University of California
Co-authored papers 4
Ronald Swanstrom
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 4
Mohan Somasundaran
University of Massachusetts Chan Medical School
Co-authored papers 2
Mohsan Saeed
Boston University Chobanian and Avedisian School of Medicine
Co-authored papers 1
Michael A Carpenter
University of Minnesota
Co-authored papers 1
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 1
Angela L Perkins
University of Minnesota
Co-authored papers 1
Kevan M Shokat
University of California San Francisco
Co-authored papers 1
William L Brown
University of Minnesota
Co-authored papers 1
Jeffrey R Johnson
Gladstone Institutes
Co-authored papers 1
Derek J Hook
Institute for Therapeutics Discovery and Development, University of Minnesota
Co-authored papers 1
Daniel A Harki
University of Minnesota
Co-authored papers 1
Michael A Parniak
University of Pittsburgh School of Medicine
Co-authored papers 1
Krishan K Pandey
Saint Louis University
Co-authored papers 1
Anurag Rathore
Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center
Co-authored papers 1
Jesse J Lipp
Research Institute of Molecular Pathology (IMP)
Co-authored papers 1
Rebecca S Levin
Howard Hughes Medical Institute, University of California San Francisco
Co-authored papers 1
Shuntai Zhou
University of North Carolina at Chapel Hill
Co-authored papers 1
Shivender M D Shandilya
University of Massachusetts Medical School
Co-authored papers 1
Ming Li
Department of Cancer Research Institute, University of South Australia
Co-authored papers 1
Yang Shen
The Second Affiliated Hospital of Nanchang University
Co-authored papers 1
Jonathan Solberg
Institute for Therapeutics Discovery and Development, University of Minnesota
Co-authored papers 1
Liang Tong
Columbia University
Co-authored papers 1
Reuben S Harris
University of Texas Health San Antonio
Co-authored papers 1
Release 1.2